Zoetis price target raised to $85 from $80 at Stifel
Stifel raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Hold rating on the shares. Zoetis delivered revenue and EPS upside in Q3, but…
Fiscal Year: January - December
Zoetis Inc. (ZTS), listed on the NYSE, has a market capitalization of $33.93B. As of Nov 06, 2026, the stock is trading at $82.11 per share@else an unavailable price , offering investors a clear view of its current market value. Zoetis Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 13.86, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Zoetis Inc. also offers a dividend yield of 2.58%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Zoetis Inc. (ZTS) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Zoetis Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Zoetis Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Zoetis Inc. is 15.23, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Zoetis Inc. (ZTS) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Zoetis Inc. (ZTS) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Zoetis Inc. (ZTS) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Zoetis Inc.. To access the full SS Score, consider upgrading your subscription.
Zoetis Inc. is a significant player in the industry sector, with a market capitalization of $33.93B and a competitive P/E ratio of 13.86. Investors should compare these metrics with industry peers to gauge whether Zoetis Inc. is outperforming or underperforming within its sector.
Stifel raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Hold rating on the shares. Zoetis delivered revenue and EPS upside in Q3, but…
Animal health company Zoetis said on Thursday it was planning cautiously for 2027 as rising veterinary costs and intensifying competition weigh on its companion-animal business.
Reports Q3 revenue $2.4B, consensus $2.3B.”Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagn...
Consensus $6.26. Narrowed revenue to a range of $9.22B to $9.32B, consensus $9.29B.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. "Our th...
Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $82 from $85 and keeps an Overweight rating on the shares.
UBS raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Neutral rating on the shares.
UBS raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Neutral rating on the shares.
Zoetis (ZTS) announced that the U.S. FDA has approved Convenia RTU for Dogs for the treatment of susceptible bacterial skin infections in dogs. For many families, administering oral antibiotics daily…
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.
Jefferies analyst Keith Devas downgraded Zoetis (ZTS) to Hold from Buy with a price target of $83, down from $103. The firm cites the company’s softer pricing environment for the…
Goldman Sachs initiated coverage of Zoetis (ZTS) with a Neutral rating and $74 price target The firm is we constructive on the company’s long-term outlook given its “industry-leading position and…
Zoetis (ZTS) announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. Knobloch currently serves on the boards of Deezer, Lazard, and Vail…
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With deca...
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will ...
Bearish flow noted in Zoetis (ZTS) with 2,293 puts trading, or 1.3x expected. Most active are Mar-27 50 puts and Mar-27 65 puts, with total volume in those strikes near…
New peer-reviewed findings published in the journal Parasites & Vectors show that Zoetis (ZTS)’ Simparica Trio protected more dogs from adult heartworm infection than NexGard Plus in a controlled, hea...
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows t...
Bearish flow noted in Zoetis (ZTS) with 2,600 puts trading, or 1.4x expected. Most active are Oct-26 65 puts and Nov-26 65 puts, with total volume in those strikes near…
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristi...
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 2.22B | 5.04% | Projected |
| 2027 | 2.33B | 5.04% | Projected |
| 2028 | 2.45B | 5.04% | Projected |
| 2029 | 2.57B | 5.04% | Projected |
| 2030 | 2.70B | 5.04% | Projected |
| 2031 | 2.83B | 4.53% | Projected |
| 2032 | 2.94B | 4.03% | Projected |
| 2033 | 3.04B | 3.52% | Projected |
| 2034 | 3.13B | 3.01% | Projected |
| 2035 | 3.21B | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 2.30B | 1.00 | 2.30B |
| 2025A | 2.28B | 1.00 | 2.28B |
| 2026E | 2.22B | 1.08 | Login |
| 2027E | 2.33B | 1.17 | Login |
| 2028E | 2.45B | 1.26 | Login |
| 2029E | 2.57B | 1.36 | Login |
| 2030E | 2.70B | 1.47 | Login |
| 2031E | 2.83B | 1.59 | Login |
| 2032E | 2.94B | 1.72 | Login |
| 2033E | 3.04B | 1.86 | Login |
| 2034E | 3.13B | 2.01 | Login |
| 2035E | 3.21B | 2.17 | Login |
| Terminal | 2.17 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.